Skip to content

Trial Summary

A Study to Determine Frequency of DNA-repair Defects in Men With Metastatic Prostate Cancer

Acronym:

PREVALENCE

ACTRN/NCT /ethics:

NCT03871816

Scientific title:

Biomarker Study to Determine Frequency of DNA-repair Defects in Men With Metastatic Prostate Cancer

Sponsor / Cooperative group:

Janssen Research & Development, LLC

Trial & Patient Characteristics

Cancer TypeProstate
Trial TypeEarly detection, diagnosis, prognosis
PhaseAll phases
Age Range18 years and older
SexMale
Tumour Stream Prostate
Cancer StageMetastatic or Widespread
Anticipated Start Date2019-04-22
Anticipated End Date2023-09-16

Participating Hospitals

HospitalAshford Cancer Centre Research
Clinical Trial CoordinatorSue Yeend
Emailsyeend@adelaidecancercentre.com.au
Phone08 8292 2240
Principal InvestigatorDr Francis Parnis
Recruitment StatusRecruiting